Introduction
============

Nonsense-mediated RNA decay (NMD) is a highly conserved eukaryotic mRNA surveillance mechanism that eliminates transcripts with a premature termination codon (PTC) located \>50-55 nts upstream of the last exon-exon junction (EJ), resulting from mutations or aberrant splicing ([@b1-ijmm-45-04-1163],[@b2-ijmm-45-04-1163]). In addition to the targeting of PTC-harboring mRNAs for surveillance, \~5-30% of cellular transcripts are finely degraded by the NMD pathway as natural substrates for modulating biological processes ([@b3-ijmm-45-04-1163],[@b4-ijmm-45-04-1163]); therefore, a disrupted NMD may be exploited to cause gene expression disruption without quality-control and fine-tuning ([@b5-ijmm-45-04-1163]). In addition, NMD impacts the cellular transcriptome in cell-type specific manners, indicating that NMD perturbation has a selective effect in increasing the levels of reported NMD substrates, such as NF-κ-B-inducing kinase *(NIK)*, transducing β like 2*(TBL2)* and N-acetyltransferase 9*(NAT9)*, in different cell lines ([@b6-ijmm-45-04-1163],[@b7-ijmm-45-04-1163]). The up-frameshift suppressor 1 homolog*(UPF1)* gene, encoding an ATP-dependent RNA helicase, is the central regulator of the NMD pathway ([@b8-ijmm-45-04-1163]). A feedback loop between the NMD and the *UPF1* gene has been reported, in which UPF1 protein was rate-limiting for NMD and responses to NMD perturbation ([@b6-ijmm-45-04-1163]). *UPF1* mutations have been deemed to play a causal role in malignant tumors, such as pancreatic adenosquamous carcinomas and inflammatory myofibroblastic tumors in our previous studies, suggesting that perturbed NMD is involved in cell hyper-proliferation, abnormal differentiation and stable activation of inflammation ([@b7-ijmm-45-04-1163],[@b9-ijmm-45-04-1163]). The modulation of the NMD pathway has been suggested to provide a benefit in several disease therapies ([@b5-ijmm-45-04-1163],[@b10-ijmm-45-04-1163]), and therefore understanding the interactions between NMD and diseases can optimize preventive and therapeutic approaches against diseases. Herein, two somatic *UPF1* mutations (c.2935_2936insA and c.2030-2081del) were identified in two patients with sporadic psoriasis scales, which perturbed the ability of the *UPF1*-NMD pathway to degrade substrates in keratinocyte cells. In the present study, to the best of our knowledge, mutated *UPF1* transcripts in psoriasis have been discovered for the first time, which indicated a role of the NMD pathway in skin disease.

A previous study hypothesized that there are keratinocyte-specific targets of the NMD pathway, and the amphiregulin *(AREG)* gene, which encodes the most abundant epidermal growth factor receptor (EGFR) ligand in keratinocytes, was suggested as one such substrate ([@b11-ijmm-45-04-1163]). *AREG* is overexpressed in a wide spectrum of epithelial diseases, including squamous cell carcinoma of the head and neck, colon cancer, lung cancer and psoriasis ([@b12-ijmm-45-04-1163]-[@b15-ijmm-45-04-1163]). *AREG* transgenic animals show epidermal acanthosis, keratinocyte hyperproliferation, hyperkeratosis, cutaneous immune cell infiltration and angiogenesis in the skin ([@b16-ijmm-45-04-1163],[@b17-ijmm-45-04-1163]). However, it is unknown how *AREG* is regulated post-transcriptionally by mRNA decay. In the present study, to the best of our knowledge, it is the first time that the potential mechanism of the *AREG*-NMD axis involved in keratinocyte cells was explored. In addition, cell activities such as differentiation, wound healing and inflammatory response, which are highly relevant to the pathogenesis of numerous skin diseases, were demonstrated to be regulated by *UPF1* in an *AREG*-dependent manner. This finding has created an opportunity to better understand the NMD pathway in keratinocytes, and indicates role of the NMD pathway in the development of diseases associated with keratinocyte morbidities.

Materials and methods
=====================

Statistical analysis
--------------------

The gene expression profiles of human paired psoriasis tissues were retrieved from Gene Expression Omnibus (GEO) database. After carefully screening the content, discarding the datasets with incomplete information and those lacking control patients, the 5 datasets with paired samples, GDS5392, GDS4602, GDS2518, GDS3539, and GDS4600, were obtained ([@b18-ijmm-45-04-1163]-[@b22-ijmm-45-04-1163]). R packages (version 3.5.2) were used to annotate the raw data and make the expression matrix ([@b23-ijmm-45-04-1163]). The median of expression level was chosen for genes matched by several probes, and paired t test was used to compare *UPF1* expression. Student\'s t-test was used for the analysis of statistical significance between two groups, and Bonferroni test was used for multiple comparisons after the analysis of variance. Data for continuous variables are expressed as the mean ± SD. All statistical analyses were performed using SPSS 21.0 software (IBM Corp.). P\<0.05 from a two-tailed test was considered to indicate a statistically significant difference.

Clinical samples
----------------

A total of 10 patients with a dermatologist-confirmed diagnosis of vulgaris psoriasis, according to the \'Consensus on diagnosis and treatment of Chinese integrative medicine for psoriasis vulgaris\', published in China ([@b24-ijmm-45-04-1163],[@b25-ijmm-45-04-1163]), were recruited at the Affiliated Hospital of Ningbo University (Ningbo, China) between January 2016 and July 2017. The patient information is shown in Table SI. The lesion scales from 6 patients (P1-P6) were independent samples, while the lesion scales and adjacent healthy samples from 4 patients (PA-PD) were paired samples. All the psoriasis patients had no other autoimmune or systemic diseases, and required a typical lesion of ≥1 cm in size that was suitable for biopsy, and the target lesion and surrounding 5 cm area were not treated with any therapeutic measures for at least 2 weeks before the sampling. Skin scales or healthy cornified epidermal layer of patients with psoriasis vulgaris were scraped by blunt scalpels with patients\' permission. The scales were promptly soaked in liquid-free nitrogen RNA sample storage solution (Beijing Bomaide Gene Technology Co., Ltd.).

Imiquimod (IMQ)-induced psoriasis-like mice
-------------------------------------------

To create the well-established psoriasis-like skin model ([@b26-ijmm-45-04-1163]), 8-11-weeks-old Balb/c mice provided by the Experimental Animal Center of Hangzhou Normal University were kept under standard laboratory conditions of 12-h light-dark cycles, 50% humidity and 24-26°C ambient temperature with free access to food and water. The mice (2 male and 2 female, 20-25 g) received a daily topical dose of 40 mg commercially available IMQ cream (5%; Zhuhai United Laboratories Co., Ltd.) on the shaved back, equivalent of a daily dose of 2.083 mg of the active compound. The control shaved skin nearby the IMQ-treated area (distance, 1.5-2 cm) was treated similarly with a control cream (Vaseline Lanette cream; Fagron). During the 7-day experiment, the topical IMQ treatment did not lead pain, and the health of all 4 mice was monitored daily. On day 7, all 4 mice were sacrificed by rapid cervical vertebra dislocation, and the skin specimens of mice were collected once the cervical tissue separation was ensured.

Reverse transcription-quantitative PCR (RT-qPCR) and mRNA sequencing
--------------------------------------------------------------------

Total RNA from model mice, clinical tissues or cells was isolated using TRIzol^®^ reagent (Invitrogen; Thermo Fisher Scientific, Inc.), and first-strand cDNA for RT-qPCR was synthesized using the PrimeScript™ RT reagent kit with gDNA Eraser according to the manufacturer\'s protocol (Takara Bio, Inc.). qPCR analysis was performed using the QuantStudio™ 7 Flex Real-Time PCR system (Thermo Fisher Scientific, Inc.) using SYBR Premix Ex Taq (Takara Bio, Inc.) with gene-specific primers listed in Table SII. The following thermocycling conditions were used: Initial denaturation at 95°C for 1 min; followed by 40 cycles of 95°C for 15 sec and 60°C for 30 sec. The disassociation stage was added to check the amplicon specificity. For transcript detections in scales tissues, *UPF1* was quantified using the allele-specific primers *UPF1* insA for c.2935_2936insA mutant, or *UPF1* del corresponding to the c.2030-2081del *UPF1* mRNA (Table SII). Specificity and efficiency of allele-specific PCR were tested with corresponding *UPF1* constructs, and further details are described in Data S1. Each mRNA quantification value represented an average of at least three measurements, and mRNA expression levels were calculated using the 2^−ΔΔCq^ method ([@b27-ijmm-45-04-1163]) after normalization to the endogenous housekeeping gene *18S* for human samples or *GAPDH* for mouse samples.

For RT-PCR, RT was performed using 1 *µ*g of total RNA with the PrimeScript™ 1st Strand cDNA Synthesis kit according to the manufacturer\'s protocol (Takara Bio, Inc.). PCR amplification was performed with nested primers (Table SIII) overlapping the coding sequence region of the *UPF1* mRNA (NCBI Reference Sequence, NM_002911.3). The following thermocycling conditions were used: Initial denaturation at 96°C for 2 min; followed by 35 cycles of 96°C for 10 sec, 55°C for 30 sec and 72°C for 2 min. The sanger sequencing was performed at Tsingke Biological Technology.

Protein detection
-----------------

For immunohistochemical (IHC), skin tissue from the model mice was fixed in 10% formalin for 24 h at room temperature and embedded in IHC-grade paraffin. Formalin-fixed paraffin-embedded sections were cut into 4-6-*µ*m sections with a microtome and deparaffinized two times in xylene, followed by serial dilutions of ethanol. After heat-induced antigen retrieval using the antigen unmasking solution (Vector Laboratories, Inc.; Maravai LifeSciences) for 30 min at 95°C, the internal peroxidase activity was quenched by incubation with 3% hydroperoxide in methanol for 15 min at room temperature, then sections were incubated in 3% bovine serum albumin (Beyotime Institute of Biotechnology) for 1 h at room temperature. The prepared sections were incubated overnight at 4°C with anti-UPF1 primary antibodies (cat. no. sc-390096; 1:100; Santa Cruz Biotechnology, Inc.). The secondary antibody (cat. no. GAMPO; 1:1; DAKO; Agilent Technologies, Inc.) was used according to the manufacturer\'s instructions for 50 min at room temperature. The intensity of IHC staining was measured using ImageJ software (version 1.52a; Media Cybernetics, Inc.).

Protein extraction for western blotting was performed using RIPA lysis buffer (Beyotime Institute of Biotechnology) with phenylmethylsulfonyl fluoride serine protease inhibitor (Beyotime Institute of Biotechnology). Protein extracts were quantified using a BCA Protein Assay kit (Beyotime Institute of Biotechnology) according to the manufacturer\'s instructions. Total proteins (30 *µ*g) were resolved by SDS-PAGE (8% gel) and visualized using Odyssey^®^ imaging system with IRDye secondary antibodies (cat. no. 926-32210; 1:1,000; LI-COR Biosciences) for 15 min at room temperature. The following primary antibodies were used overnight at 4°C: Anti-UPF1 (cat. no. sc-166092; 1:200; Santa Cruz Biotechnology, Inc.), anti-AREG (cat. no. GTX100986; 1:200; GeneTex, Inc.), and anti-GAPDH (cat. no. M20006L; 1:1,000; Abmart Pharmaceutical Technology Co., Ltd.). Semi-quantification was performed using ImageJ software.

Cell culture and transfection
-----------------------------

Primary cultured normal human keratinocytes (HEKα), immortalized nontumorigenic human keratinocyte-derived cell line (HaCaT) and 293T cell line were purchased from the Shanghai Institute of Biochemistry and Cell Biology. HaCaT and 293T cells were cultured in DMEM with 10% FBS (Biological Industries), and HEKα cells were cultured in EpiLife Medium with 60 *µ*M calcium with Keratinocyte Growth Supplement (Gibco; Thermo Fisher Scientific, Inc.). All cells were incubated at 37°C in a humidified 5% CO~2~ incubator.

For plasmid and small interfering (si)RNA transfection, 4×10^4^ cells/well in 6-well plates were cultured overnight and then transfected using the GeneTran Reagent (Biomiga, Inc.). For co-transfection targeting both *UPF1* and *AREG*, constructs were transfected at the same time; however, when constructs targeting the same gene were co-transfected, construct for knockdown was transfected first, then the overexpression construct was transfected 24 h later. Total mRNA and protein of cells were collected 48 h after transfection.

Constructs and oligonucleotides
-------------------------------

A short hairpin RNA (shRNA) sequence specifically targeting *UPF1* (Table SIV) was cloned into Phblv-U6-puro (provided by Professor Fan Handong, Hangzhou Normal University) by *Bam*HI and *Eco*RI digestion. The siRNA targeting *AREG* (targeted sequence, CCACAAATACCTGGCTATA) and a scrambled sequence were purchased from Guangzhou RiboBio Co., Ltd. The *UPF1* insA and *UPF1* del plasmids were constructed based on the pCMV-MYC-*UPF1* vector (provided by Professor Lynne E. Maquat, University of Rochester). Primers for site-directed mutagenesis (Table SIV) were designed by QuickChange Primer Design (Agilent Technologies, Inc.) and applied with the KOD-Plus-PCR enzyme (Toyobo Life Science). Residual templates were digested by *Dpn*I (New England Biolabs, Inc.) at 37°C for 5 h. The *AREG* gene open reading frame (ORF) with or without the 3′ untranslated region (3′UTR), which was referred as *AREG*-3′UTR-pEGFP or *AREG*-ORF-pEGFP, respectively, was cloned into the pEGFP-N1 vector (provided by Dr Wang Miao, Hangzhou Normal University) using the *Hind*III and *Bam*HI restriction sites. The primer sequences used are listed in Table SIV. The *AREG* 3′UTR sequence was amplified and cloned into the dual-luciferase reporter construct pEZX-FR02 (GeneCopoeia, Inc.) by double digestion with *Eco*RI and *Spe*I (the primer sequences used are listed in Table SIV) to generate the pEZX-*AREG*-3′UTR construct.

Half-life analysis
------------------

The 293T cells were transfected with or without sh*UPF1* and the transcription in cells was inhibited by incubation with 20 mg/ml 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole (DRB; Enzo Life Sciences, Inc.) dissolved in DMSO. Total RNA was extracted at 0, 3, 5, 7, and 10 h following the inhibition of transcription, and AREG mRNA levels were measured by RT-qPCR, as described above. Quantity of RNA at each time point was determined by comparison with standard curves generated by amplification of the time-zero RNA sample.

Dual-luciferase reporter assays
-------------------------------

The pEZX-*AREG*-3′UTR transfected 293T cells were co-transfected with or without sh*UPF1* using the GeneTran™ III reagent (Biomiga, Inc.). At 80% confluence and 48 h post transfection, cells were collected and the activities of both firefly luciferase (FLuc) and *Renilla* luciferase (RLuc) were measured according to the instructions of the dual luciferase reporter assay system (GeneCopoeia, Inc.). The internal standard for transfection efficiency was normalized to RLuc activity.

Cell proliferation and migration assays
---------------------------------------

HaCaT and HEKα cells were plated at a density of 2×10^4^ cells/well in 96-well plates and incubated overnight. The proliferation index was measured using a Cell Counting Kit-8 (Dojindo Molecular Technologies, Inc.) at 48 h according to the manufacturer\'s instructions. For the cell wound healing assay, cells in the logarithmic growth phase were seeded in 24 well plates at a density of 5×10^5^ cells/ well. When the cells reached 100% confluence, a straight line was drawn in the cells in each well with a 10-*µ*l pipette tip and the cells were serum-starved. Representative images (magnification, ×20) of wound closure were captured at 0, 6, 12, 24, and 48 h with an inverted microscope, and the wound area was measured using ImageJ software. The percentage of wound coverage was calculated by the difference in area between indicated time point and 0 h, divided by the area at 0 h.

Accession codes
---------------

The gene sequences used in the current study are publicly available at the GenBank \[*UPF1* mRNA (NM_002911.3) and *AREG* mRNA (NM_001657.4)\]. Data on *UPF1* mutations were deposited in the GenBank under accession numbers MH183202 (*UPF1* c.2935_2936 insA) and MK089816 (*UPF1* c.2030_2081 del 50 nts).

Results
=======

Abnormal expression of UPF1 in psoriasis and psoriasis-like mouse model
-----------------------------------------------------------------------

First, a paired samples test for *UPF1* expression was concluded using GEO datasets GDS5392, GDS4602, GDS2518, GDS3539 and GDS4600. An analysis of 186 paired psoriasis and corresponding normal tissues showed that the *UPF1* mRNA expression increased significantly in psoriasis ([Fig. 1A](#f1-ijmm-45-04-1163){ref-type="fig"}). Increased *UPF1* mRNA levels were also observed in sporadic patients\' skin scales obtained in the current study, including four paired tissues (PA, PB, PC and PD; [Fig. 1B](#f1-ijmm-45-04-1163){ref-type="fig"}), six independent scales and four independent normal tissues. The IMQ induced psoriasis-like skin showed morphological characteristics consistent with the symptoms of human psoriasis ([@b28-ijmm-45-04-1163]), such as skin thickening ([Fig. S1 and Data S1](#SD1-ijmm-45-04-1163){ref-type="supplementary-material"}) and hyperkeratosis ([Fig. 1D](#f1-ijmm-45-04-1163){ref-type="fig"}), and RT-qPCR showed that the psoriasis-like skin expressed higher mRNA levels of proinflammatory cytokines and chemokines associated with psoriasis including *AREG*, interleukin (*IL)-17A*, *IL-6*, tumor necrosis factor*-α* and *C-X-C motif chemokine 2* (data not shown). All 4 paired tissues from IMQ-induced psoriasis-like skin exhibited increased *UPF1* mRNA levels ([Fig. 1C](#f1-ijmm-45-04-1163){ref-type="fig"}), while protein levels were significantly decreased in 2/4 pairs, as detected by IHC ([Fig. 1D and E](#f1-ijmm-45-04-1163){ref-type="fig"}). Abnormal *UPF1* expression levels were also revealed by GEO database analysis for three other skin diseases tissues, including the Marfan syndrome, squamous cell carcinoma and melanoma tissues ([Fig. S2 and Data S1](#SD1-ijmm-45-04-1163){ref-type="supplementary-material"}). As *UPF1* mRNA is a natural substrate of the NMD pathway, as well as a rate limiting element for NMD ([@b6-ijmm-45-04-1163]), the abnormal expression of *UPF1* in those skin disease tissues was presumed to indicate a disturbed NMD pathway in the keratinocyte cells. According to the cell-type specific manner of NMD, multiple reported NMD substrates, which have been reported to be sensitive to *UPF1* depletion in different cell lines ([@b6-ijmm-45-04-1163]-[@b8-ijmm-45-04-1163]), were tested by RT-qPCR in sh*UPF1* treated keratinocyte cells in a preliminary study. Three well-characterized endogenous NMD substrates, *NIK, TBL2* and *NAT9* mRNAs, were verified to increase in level in response to *UPF1*-depletion in the studied 293T and keratinocyte cells (data not shown), thus, the *NIK*, *TBL2* and *NAT9* mRNAs were selected to presented the NMD endogenous substrates. In the psoriasis-like mouse model, a disturbed NMD was hinted by the accumulation of NIK, TBL2 and NAT9 mRNAs in some paired lesions ([Fig. 1F](#f1-ijmm-45-04-1163){ref-type="fig"}).

Aberrant transcripts of UPF1 in psoriasis scales
------------------------------------------------

The skin scales are mostly composed of corneocytes ([@b29-ijmm-45-04-1163]); thus, the tissues may have been fragile for RNA sequencing. Five out of ten psoriasis scales from sporadic psoriasis patients were demonstrated to be reliable sources of RNA, as PCR fragments of *UPF1* and *AREG* mRNAs were amplified successfully in these tissues ([Fig. S3 and Data S1](#SD1-ijmm-45-04-1163){ref-type="supplementary-material"}). Among the 5 available scales for RNA sequencing, 2 aberrant UPF1 transcripts were identified in patients A and B, and neither mutant was detected in the corresponding healthy epidermal tissue. The heterozygous mutation c.2935_2936insA ([Fig. 2A](#f2-ijmm-45-04-1163){ref-type="fig"}) identified in patient A (a 36-year-old man with an affected buttock) generated an in-frame PTC located 136 nts upstream of the exon 22-23 junction ([Fig. 2B](#f2-ijmm-45-04-1163){ref-type="fig"}). The heterozygous mutation c.2030-2081del ([Fig. 2A](#f2-ijmm-45-04-1163){ref-type="fig"}) in patient B (a 48-year-old woman with affected arms) was spliced by the use of noncanonical splice donor/acceptor within exon 15 sharing a GGCC sequence, which generated a PTC 93 nts upstream of the exon 16-17 junction ([Fig. 2B](#f2-ijmm-45-04-1163){ref-type="fig"}). There was no detectable mutation in the corresponding DNA or flanking introns, and, to the best of our knowledge, these two mutations had not been reported prior to the present study. The canonical ORF of *UPF1* was disrupted in both aberrant transcripts, and the mutants were predicted to produce truncated proteins losing serine-glutamine cluster domain or the helicase domain ([Fig. 2B](#f2-ijmm-45-04-1163){ref-type="fig"}).

To analyze the expression of *UPF1* transcripts in psoriasis scales, specific primers were designed, according to the aberrant sequences ([Fig. 2C](#f2-ijmm-45-04-1163){ref-type="fig"}). The specificity and efficiency of RT-qPCR for *UPF1* insA were tested with allele-specific amplification. Transcript analysis demonstrated that the aberrant mutants were only detectable in psoriasis scales, whereas the wild-type (WT) transcripts were expressed in both the scale lesions and healthy cornified epidermal layer, showing a decrease in lesions ([Fig. 2D](#f2-ijmm-45-04-1163){ref-type="fig"}).

Perturbation of NMD results from UPF1 insA and UPF1 del transcripts
-------------------------------------------------------------------

The selective accumulation of the PTC-harboring transcripts in lesions but not in the adjacent normal tissues raised the possibility that the NMD pathway was perturbed in the two scales. Consistent with this hypothesis, it was found that the expression level of preselected NMD substrates, *NIK*, *TBL2* and *NAT9*, was elevated in the psoriasis scales compared with normal control samples ([Fig. 3A](#f3-ijmm-45-04-1163){ref-type="fig"}).

Successful overexpression and knockdown of *UPF1* was confirmed ([Fig. S5A and Data S1](#SD1-ijmm-45-04-1163){ref-type="supplementary-material"}). The subsequent transfection of the *UPF1* insA, *UPF1* del or *UPF1* WT constructs into *UPF1*-depleted 293T cells revealed that the mutated transcripts were expressed at a slightly lower steady-state level than *UPF1* WT at both the mRNA and protein levels ([Fig. 3B and C](#f3-ijmm-45-04-1163){ref-type="fig"}; lanes 3-5). As predicted above, the mutants generated minor protein bands that were predicted to be \~114 kDa for *UPF1* insA and 78 kDa for *UPF1* del ([Fig. 3C](#f3-ijmm-45-04-1163){ref-type="fig"}; lanes 4-5), as compared with the 128 kDa full-length UPF1 protein ([Fig. 3C](#f3-ijmm-45-04-1163){ref-type="fig"}; lane 3). The truncated UPF1 protein in psoriasis scales was not confirmed, as no protein sample could be collected. Subsequently, the expression levels of NMD substrates, which depended on mutated *UPF1*, were examined. Unlike *UPF1* WT, which could rescue NMD activity in *UPF1*-depleted cells to decrease the level of NMD substrates, *UPF1* insA and *UPF1* del did not impact the *NIK*, *TBL2* or *NAT9* mRNA expression levels, indicating that the two mutants lacked a detectable NMD function ([Fig. 3D](#f3-ijmm-45-04-1163){ref-type="fig"}).

Identification of AREG mRNA as an NMD substrate depend on the 3′UTR of AREG
---------------------------------------------------------------------------

After verifying the disruption of the NMD pathway by *UPF1* mutants, gene regulation under a deficient NMD pathway was explored. As NMD targets diverse substrates and governs RNA homeostasis in a cell-specific manner ([@b6-ijmm-45-04-1163]), it was hypothesized that NMD deficiency would allow partial targets to be stabilized, leading to a disordered gene expression in a keratinocyte-specific manner. As the most abundant EGFR ligand gene in keratinocytes ([@b30-ijmm-45-04-1163]), *AREG* mRNA was identified as a candidate for the NMD pathway, since it harbors an EJ in its 3′UTR, which could trigger moderate NMD ([Fig. 4A](#f4-ijmm-45-04-1163){ref-type="fig"}) ([@b1-ijmm-45-04-1163]). The expression level of *AREG* mRNA was increased in psoriasis tissues and *UPF1*-depleted keratinocyte cells, while *UPF1* overexpression conversely decreased *AREG* mRNA levels in keratinocytes ([Fig. 4B and C](#f4-ijmm-45-04-1163){ref-type="fig"}). Consistent with the well-established NMD substrates noted above, the dysregulation of *AREG* mRNA under *UPF1* depletion could be rescued by *UPF1* WT, but not by *UPF1* insA or *UPF1* del ([Fig. 4D](#f4-ijmm-45-04-1163){ref-type="fig"}). This effect was also observed at the protein level, as shown by western blotting ([Fig. 4E](#f4-ijmm-45-04-1163){ref-type="fig"}).

Given that transcript destabilization is the hallmark of direct NMD targets ([@b31-ijmm-45-04-1163]), RNA half-life analysis was performed on DRB-treated 293T cells with an inhibited transcriptional activity ([@b32-ijmm-45-04-1163]); it was found that *AREG* mRNA was stabilized \~1.23-fold in response to *UPF1* depletion ([Fig. 5A](#f5-ijmm-45-04-1163){ref-type="fig"}). To verify the NMD-triggering effect of *AREG* mRNA, *AREG* vector with or without its 3′UTR sequence was constructed ([Fig. 5B](#f5-ijmm-45-04-1163){ref-type="fig"}), and the overexpression and knockdown of *AREG* was confirmed ([Fig. S5B and Data S1](#SD1-ijmm-45-04-1163){ref-type="supplementary-material"}). After knocking down endogenous *UPF1* and *AREG* in 293T cells, no significant change was identified in the expression of exogenous *AREG* following transfection with *AREG* without the 3′UTR ([Fig. 5C](#f5-ijmm-45-04-1163){ref-type="fig"}; lanes 5 and 6); however, the expression of *AREG* following transfection with AREG with 3′UTR was increased significantly ([Fig. 5C](#f5-ijmm-45-04-1163){ref-type="fig"}; lanes 7 and 8), which indicated that the 3′UTR region was indispensable for NMD targeting. The current study further examined whether the 3′UTR of *AREG* was targeted by NMD via the dual-luciferase reporter system pEZX-FR02 ([Fig. 5D](#f5-ijmm-45-04-1163){ref-type="fig"}). The results showed that the insertion of the *AREG* 3′UTR to pEZX-FR02 increased the FLuc activity following *UPF1* depletion, indicating that this sequence was adequate for the triggering NMD ([Fig. 5E](#f5-ijmm-45-04-1163){ref-type="fig"}).

NMD regulates keratinocyte homeostasis by regulating AREG
---------------------------------------------------------

*UPF1* knockdown has been reported to result in cell apoptosis ([@b33-ijmm-45-04-1163],[@b34-ijmm-45-04-1163]), while *AREG* positively regulates the proliferation of keratinocytes ([@b11-ijmm-45-04-1163]). Successful target gene expression regulation by *UPF1* and *AREG* vectors was confirmed in keratinocyte cells ([Fig. S6 and Data S1](#SD1-ijmm-45-04-1163){ref-type="supplementary-material"}), and the cell morphology and area of cells did not change significantly ([Fig. S7 and Data S1](#SD1-ijmm-45-04-1163){ref-type="supplementary-material"}). The viability of *UPF1*-depleted HaCaT and HEKα cells was decreased, and the inhibition of *AREG* further decreased cell viability in these cells ([Fig. 6A](#f6-ijmm-45-04-1163){ref-type="fig"}). These results were confirmed by determining the mRNA expression levels of proliferation marker protein Ki67, and BCL2 associated agonist of cell death*(BAD)* ([Fig. 6B](#f6-ijmm-45-04-1163){ref-type="fig"}). Epidermal acanthosis, hyperkeratosis and angiogenesis have been previously detected in the skin of AREG transgenic animals ([@b35-ijmm-45-04-1163]), which indicates an ability of *AREG* to affect cell differentiation. *UPF1* depletion markedly inhibited the expression of the differentiation gene keratin-5*(K5)*, the terminal differentiation marker filaggrin *(FLG)* and keratin-10*(K10)*. The expression levels of the differentiation markers were reversed in HaCaT and HEKα cells when *AREG* inhibition was coupled with *UPF1* depletion ([Fig. 6C](#f6-ijmm-45-04-1163){ref-type="fig"}).

Keratinocytes in which terminal differentiation is halted undergo changes in cell migration, and keratinocytes can repair wounds partly by migration ([@b36-ijmm-45-04-1163]). A wound healing assay was therefore performed to estimate the extent to which *UPF1* depletion promoted cutaneous wound healing. *UPF1* depletion increased the ability of both HaCaT and HEKα cells to migrate and re-epithelialize as demonstrated by the changes in cell-free areas. Following double knockdown of *AREG* and *UPF1* in keratinocytes, the cell re-epithelialization was impaired compared with the shUPF1 group ([Fig. 6D and E](#f6-ijmm-45-04-1163){ref-type="fig"}). The perturbed NMD in the sh*UPF1* group induced the expression of motility markers, cyclooxygenase-2 (*COX-2)*, matrix metalloproteinase 1 (*MMP1)* and snail family transcriptional repressor 1*(SNAI1)* compared with control group, while double knockdown of *AREG* and *UPF1* lost this capacity ([Fig. 6F](#f6-ijmm-45-04-1163){ref-type="fig"}). Keratinocytes also produce proinflammatory mediators that react against damage ([@b37-ijmm-45-04-1163]). In the current study, an increased expression of chemokine (C-C motif) ligand 20*(CCL20)* and human recombinant GRO-α*(CXCL1)* was observed following NMD disruption in HaCaT and HEKα cells. The increased expression of these proinflammatory chemokines following NMD disruption was restored by *AREG* knockdown in these cells ([Fig. 6F](#f6-ijmm-45-04-1163){ref-type="fig"}).

Discussion
==========

To investigate the NMD pathway in skin diseases, the core element *UPF1* was examined in patients with psoriasis and psoriasis-like mouse models. Psoriasis datasets from the GEO, human psoriasis scales and IMQ-induced skin inflammation samples all displayed increased *UPF1* mRNA levels compared with their respective controls. In addition, analysis for several other skin diseases was conducted by analyzing *UPF1* expression profiles acquired from the GEO database. An independent sample test for Marfan syndrome (GDS2960) showed a significantly increased *UPF1* expression in lesions compared with normal tissues, and multiple comparisons for squamous cell carcinoma (GDS2200) and melanoma (GDS1375) showed a high *UPF1* expression in squamous cell carcinoma compared with actinic keratosis or normal tissues, and melanoma and benign nevi compared with normal tissues ([@b26-ijmm-45-04-1163]-[@b38-ijmm-45-04-1163]). A negative feedback regulatory network that directly acts on *UPF1* in response to NMD perturbation has been identified in a previous study which demonstrated that *UPF1* itself is a natural substrate of the NMD pathway ([@b6-ijmm-45-04-1163]). Overexpression of *UPF1* indicated by the GEO datasets analysis herein hinted at an abnormal NMD in several skin diseases besides psoriasis. Furthermore, although increased *UPF1* mRNA levels were observed in IMQ-induced psoriasis-like skin, this result was not confirmed at the protein levels in two mice. Expression levels of well-characterized NMD substrates, *NIK*, *TBL2* and *NAT9* mRNAs were also increased in mouse models of psoriasis, suggesting the possibility of *UPF1*-related NMD perturbation in psoriasis. The protein level of the NMD substrates was not determined in the current study, as the NMD pathway regulates substrates mainly by destabilizing the mRNAs, while protein level may be affected by translation efficiency or protein degradation ([@b32-ijmm-45-04-1163]).

By sanger sequencing in 5 scales, two somatic *UPF1* transcripts were identified in 2 patients with sporadic psoriasis. The c.2935_2936insA and c.2030-2081del mutations in *UPF1* mRNAs both disrupted the conventional reading frame and resulted in PTCs. The PTC-*UPF1* transcripts should be immediately degraded by NMD under well-balanced RNA surveillance, while the abnormal mRNAs may escape degradation under exceptional circumstances, and consequently be translated into truncated proteins. Fully functional UPF1 is indispensable to the NMD pathway ([@b1-ijmm-45-04-1163]), while UPF1 without C-terminal domains has been assumed to fail in autophosphorylation or RNA unwinding ([@b38-ijmm-45-04-1163]). The truncated UPF1 protein disturbed NMD function, as demonstrated by the upregulation of the NMD-sensitive mRNAs *NIK*, *TBL2* and *NAT9*. The calponin homology domain retained in truncated UPF1 protein has been shown to exert an inhibitory effect on helicase activity, and the inhibition can be relieved by UPF2 binding ([@b39-ijmm-45-04-1163]). Although in the current study RT-qPCR analysis showed that the expression of *UPF1* WT was retained in the psoriasis scales, it was speculated that the truncated protein may competitively interact with UPF2 and disturb the helicase activity of residual full-length UPF1 protein. In *UPF1*-depleted 293T cells, the mutated *UPF1* exhibited slightly lower steady-state levels than *UPF1* WT, at both the mRNA and protein levels. One explanation for this result is that the mutants were destabilized by redundant endogenous UPF1. Of note, although the expression level of *UPF1* was found to be increased in psoriasis data from the GEO database, IMQ-mice and psoriasis scale tissues, these data were derived from chip detection or RT-qPCR and depended on the specified nucleotide site binding, without considering the overall sequences of the transcripts or proteins. In fact, the increased expression of total *UPF1* mRNA in psoriasis may be due to the accumulation of aberrant transcripts, at least in these 2 psoriasis scales. It remains to be elucidated whether the c.2935_2936insA and c.2030_2081del *UPF1* could be representative in psoriasis, and further data should be collected to verity this hypothesis. In the present study, the abnormal *UPF1* transcripts, which were identified in two patients with sporadic psoriasis, were employed to reduce UPF1 activity. These finding indicated gene dysregulation related with NMD deficiency.

It was also concluded that *AREG* is an important substrate of the NMD pathway in keratinocytes. The EJ in the 3′UTR of *AREG* mRNA, which is present at low levels among cellular transcripts, could trigger the NMD pathway ([@b1-ijmm-45-04-1163],[@b3-ijmm-45-04-1163]). AREG has been reported to be the most abundant EGFR ligand in keratinocytes ([@b30-ijmm-45-04-1163]) and overexpressed in a wide spectrum of epithelial diseases, including squamous cell carcinoma of the head and neck, colon cancer, lung cancer and psoriasis ([@b12-ijmm-45-04-1163]-[@b15-ijmm-45-04-1163]). A negative association was identified between the expression levels of *AREG* and *UPF1* in keratinocytes, and the upregulation of *AREG* could be rescued by the recovery of *UPF1* WT, rather than the mutated *UPF1*. Based on the premise that post-transcriptional regulation of the *AREG* expression has little involvement in the NMD pathway, it was empirically determined in a half-life assay under inhibited UPF1 transcription *in vitro* that *AREG* mRNA was directly targeted by the NMD pathway. These results confirmed a previous hypothesis that *AREG* expression was regulated by NMD post-transcriptionally, rather than by impacting its transcription level ([@b32-ijmm-45-04-1163]). In the current study, only *AREG* transcripts with the 3′UTR sequence could be regulated by NMD, and the results based on FLuc/RLuc dual-luciferase reporter system indicated that the 3′UTR sequence of *AREG* mRNA was sufficient to trigger the NMD pathway. It was therefore concluded that *AREG* mRNA was a primary NMD substrate, and that the mechanism through which *AREG* was degraded by NMD was dependent on its 3′UTR.

According to the classic NMD mechanism, termination codons situated \>50-55 nts upstream of an EJ are typically expected to trigger mRNA surveillance, depending on a multi-subunit protein complex, the exon junction complex (EJC) ([@b3-ijmm-45-04-1163]). However, the distance between the termination codon (Ter) and the EJ downstream in the *AREG* is only 18 nts, which may prevent the mRNA from assembling a stable EJC. According to a previous report, \~50% of EJCs were mapped to a non-canonical position, where no binding sites were predicted to exist ([@b40-ijmm-45-04-1163]), suggesting that the *AREG* might be targeted by NMD by a 3′UTR-dependent but EJC-independent pathway. The relative increase in the half-life of *AREG* mRNA in *UPF1*-depleted cells was just 1.23-fold, which was smaller than that of several documented substrates with a similar NMD-inducing feature (Table SV) ([@b8-ijmm-45-04-1163]). As the NMD pathway targets natural substrates in different magnitudes ([@b8-ijmm-45-04-1163]), it was speculated that the recognition reaction between *AREG* and the NMD pathway may be weaker compared with other endogenous substrates. *AREG* may contribute to diverse biological mechanisms depending on its dominance in keratinocytes, which is in line with the cell-specific character of NMD.

The NMD pathway governs different subsets of substrates and participates in diverse, essential homeostatic mechanisms in different cells ([@b6-ijmm-45-04-1163]), and the perturbation of NMD influences cellular homeostasis in a cell-specific manner. By contrast, aberrant *UPF1* may lead to reprogramming towards a more malignant state in premalignant glandular pancreatic cells ([@b9-ijmm-45-04-1163]), and may drive a proinflammatory response in lung epithelial cells ([@b7-ijmm-45-04-1163]). As shown in HaCaT and HEKα keratinocytes used in the current study, *UPF1* depletion decreased viability and differentiation, induced re-epithelialization, with increased expression of motility markers *SNAI1*, *COX-2* and *MMP1*, and upregulated the expression of the chemokines *CCL20* and *CXCL1*.

NMD deficiency has been reported to result in cell apoptosis though preferentially increasing the level of the growth arrest and DNA damage inducible b in 293 cells ([@b33-ijmm-45-04-1163]). *Double Homeobox 4* mRNA, an NMD substrate, has also been shown to cause apoptosis in muscle cells ([@b34-ijmm-45-04-1163]). The BAD protein has been reported to be a proapoptotic factor inactivated by the AKT signaling ([@b41-ijmm-45-04-1163]). In the present study, the expression of *BAD* mRNA was upregulated in the *UPF1*-depleted keratinocytes. As a major autocrine growth factor for human keratinocytes, AREG plays an important, positive role in keratinocyte proliferation ([@b30-ijmm-45-04-1163]). Unlike the previously reported role of *AREG* in inducing hyperproliferation by itself ([@b11-ijmm-45-04-1163]), the disruption of NMD, along with stabilization of *AREG* observed in the current study, decreased the proliferation of keratinocytes, and following the depletion of endogenous *AREG*, the viability of keratinocytes further decreased, indicating an anti-apoptotic role of *AREG*. NMD has been shown to extensively impact gene expression either directly, by targeting degradation, or indirectly, via downstream cascades ([@b1-ijmm-45-04-1163]). NMD deficiency in keratinocytes may mediate a proapoptotic effect in advance and abrogate the proliferation-promoting effect of *AREG* alone, as shown in a previous study, in which oncogene-induced proliferation was inhibited by cellular senescence ([@b42-ijmm-45-04-1163]).

*AREG* is considered to prevent keratinocyte differentiation, and the suppression of *AREG* to irreversibly upregulate genes involved in keratinocyte differentiation ([@b11-ijmm-45-04-1163],[@b43-ijmm-45-04-1163]). The present data demonstrated that the depletion of *UPF1* in HaCaT and HEKα cells downregulated the expression of differentiation markers by targeting *AREG*. Skin diseases, such as psoriasis, can be triggered by physical injury in susceptible patients (known as the Koebner phenomenon), and it is critical to understand the elements participating in processes occurring in cutaneous wounds ([@b44-ijmm-45-04-1163],[@b45-ijmm-45-04-1163]). Additionally, it has been suggested that endogenous *AREG* modulates tissue repair and regulates the migration of several cell types, such as breast cancer cells ([@b46-ijmm-45-04-1163],[@b47-ijmm-45-04-1163]). The current findings confirmed that NMD perturbation in keratinocytes promoted wound re-epithelialization by adjusting endogenous *AREG* levels. Previous reports have shown that the overexpression of exogenous *AREG* in keratinocytes does not result in marked increases in cell migration ([@b48-ijmm-45-04-1163]), and the contrasting results in the present study highlight the unique character of NMD deficiency in cellular balance. *AREG* has also been reported to mediate inflammatory action in keratinocytes ([@b49-ijmm-45-04-1163],[@b50-ijmm-45-04-1163]). In the present study, NMD normally suppressed inflammatory activation by targeting *AREG* mRNA; when this suppression was alleviated due to *UPF1* deficiency, the stabilization of *AREG* mRNA led to a high expression of the proinflammatory chemokines, which may contribute to triggering immune cell infiltration and angiogenesis.

The present data supported a model in which NMD normally regulated *AREG* abundance to maintain the homeostasis in keratinocytes. NMD deficiency caused by *UPF1* alterations could disrupt proliferation, inhibit cell differentiation, promote wound healing, and activate inflammation response, by regulating *AREG* post-transcriptionally in keratinocytes, leading to indirect impacts on downstream gene cascades.

To the best of our knowledge, this is the first study revealing mutated *UPF1* transcripts in psoriasis and investigating the relationship between the *AREG-*NMD axis and homeostasis of keratinocytes. These findings of aberrant *UPF1* expression in psoriasis and disruption of gene regulation at the post-transcriptional level might be useful for understanding the full development of keratinocyte morbidity. Furthermore, these results suggested that therapies involving NMD intervention may have the potential to ameliorate skin diseases or even other diseases related to abnormal cell differentiation, wound healing or inflammatory responses, through rescuing the dysregulation of multiple NMD substrates, such as *AREG*, either directly or via indirect regulation cascades. Mouse tissue samples were suitable for analysis; however, the human scale samples are fragile and were only selected due to the lack of availability of biopsy samples. The role of the *AREG*-NMD axis in treated psoriasis is still unknown, as all patients recruited in the current study were not treated with any therapy for at least 2 weeks before the sampling, and it was challenging to follow the patients further without electronic medical records in the hospital system. In order to determine whether the mutated *UPF1* could be representative in psoriasis, the quality and quantity of samples should be improved in the future, and an animal model with gene modification could be used for *in vivo* verification. In addition, the role of the *AREG*-NMD axis in skin diseases with abnormal *UPF1* expression levels, such as Marfan syndrome, non-melanoma skin cancer and malignant melanoma, should be investigated further.
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![Abnormal expression of *UPF1* in psoriasis. (A) Paired sample t-test for 186 paired psoriasis samples from GEO datasets (GDS5392, GDS4602, GDS2518, GDS3539 and GDS4600). (B) Student\'s t-test for UPF1 mRNA levels in 10 psoriasis scales and 8 healthy cornified epidermal layer samples. Among the samples, four paired tissues were indicated with black lines. The *UPF1* expression increased in the psoriasis group; 3/4 paired samples showed an upregulated expression level of *UPF1*. (C) Mice received a daily topical IMQ cream to induce psoriasis-like skin. The expression of *UPF1* increased in all four psoriasis-like tissues, as compared with the paired normal skin tissue samples. (D) The expression of UPF1 protein distributed throughout the cytoplasm in mouse skin was detected by IHC. The white arrows indicate positive UPF1 protein staining, and the red arrows indicate skin hyperkeratosis in IMQ-treated samples. (E) IHC staining was suantified using ImageJ software. The UPF1 protein decreased in 2/4 paired samples. (F) The mRNA expression of three NMD substrates, *NIK*, *TBL2* and *NAT9*, were higher in psoriasis-like skin compared with normal tissue. Data are presented as the mean ± SD from three independent experiments. ^\*^P\<0.05 and ^\*\*\*^P\<0.001. n.s., not significant; *UPF1*, up-frameshift suppressor 1 homolog; IMQ, imiquimod; IHC, immunohistochemistry; NMD, nonsense-mediated RNA decay; *NIK*, NF-κ-B-inducing kinase; *TBL2*, transducing β like 2; *NAT9*, N-Acetyltransferase 9; PS, psoriasis or IMQ-treated psoriasis-like skin; PN, normal cornified epidermal layer.](IJMM-45-04-1163-g00){#f1-ijmm-45-04-1163}

![Somatic mutations of *UPF1* transcripts in patients with psoriasis vulgaris. (A) Sequencing traces corresponding to UPF1 insA (GenBank ID, MH183202) in patient A and *UPF1* del (GenBank ID, MK089816) in patient B. The red frame indicates the insertion or shared sequence for splicing. The sequencing primers used were F4/R4 and F3/R3 from Table SIII. (B) Schematic representation of the aberrant mRNAs and proteins. The mutations and PTCs are indicated in red, while the EJs and Ters are presented in black in the mRNA schematic. The functional domains of UPF1 are shown in the protein schematic, and the gray lines indicate that the amino acid sequence was changed until the Ter. (C) Primers specific to *UPF1* mutants or *UPF1* WT were designed to detect the expression of *UPF1* transcripts in the 2 patients. (D) The portions of *UPF1* insA and *UPF1* del were evaluated by reverse transcription-quantitative PCR. Mutated *UPF1* transcripts were only detectable in the psoriasis scales. Data are presented as the mean ± SD from three independent experiments. ^\*\*\*^P\<0.001. *UPF1*, *up-frameshift suppressor 1 homolog*; PTC, premature termination codon; EJ, exon-exon junction; Ter, termination codon; WT, wild-type; PS, psoriasis scales; PN, normal cornified epidermal layer; SQ, serine-glutamine; CH, calponin homology.](IJMM-45-04-1163-g01){#f2-ijmm-45-04-1163}

![Aberrant *UPF1* transcripts disrupt the function of the NMD pathway. (A) The expression level of *NIK*,*TBL2* and *NAT9* showed an increase in psoriasis scales from patients A and B compared with PN samples. (B) 293T cells were transfected with the sh*UPF1* construct, and with the *UPF1* WT, *UPF1* insA or *UPF1* del vector 24 h later. *UPF1* transcript expression was quantified 48 h after transfection. The expression levels of *UPF1* insA and *UPF1* del were lower than that of *UPF1* WT following transfection with the respective constructs. (C) Western blot analysis was used to measure the expression of UPF1 protein isoforms, and GAPDH was used as a control. The UPF1 insA and UPF1 del generated minor protein bands, the predicted molecular weights are indicated. (D) mRNA expression levels of NMD substrates *NIK*, *TBL2* and *NAT9* were increased in *UPF1*-depleted 293T cells, as detected by reverse transcription-quantitative PCR. Data are presented as the mean ± SD from three independent experiments. ^\*\*\*^P\<0.001. n.s., not significant. *UPF1*, up-frameshift suppressor 1 homolog; NMD, nonsense-mediated RNA decay; *NIK*, NF-κ-B-inducing kinase; *TBL2*, transducing β like 2; *NAT9*, N-Acetyltransferase 9; WT, wild-type; PS, psoriasis scales; PN, normal cornified epidermal layer.](IJMM-45-04-1163-g02){#f3-ijmm-45-04-1163}

![Expression of *AREG* is regulated by the NMD pathway. (A) Schematic representation of *AREG* mRNA. The EJ in the 3′UTR was presumed to be an NMD pathway triggering feature. (B) *AREG* expression was increased in the psoriasis scales from patients A and B compared with their respective PN samples. (C) Keratinocytes were transfected with sh*UPF1* or *UPF1* WT constructs. The *AREG* mRNA level was regulated by *UPF1* expression in HEKα and HaCaT cells, as quantified 48 h after transfection. (D) 293T cells were transfected with UPF1 expression vectors after transfection with sh*UPF1*, and *AREG* mRNA levels were quantified 48 h after transfection. (E) AREG protein expression levels were measured by western blotting, and GAPDH was used as a control. AREG levels were only decreased by *UPF1* WT. Data are presented as the mean ± SD from three independent experiments. ^\*\*\*^P\<0.001. *AREG*, amphiregulin; NMD, nonsense-mediated RNA decay; EJ, exon-exon junction; WT, wild-type; *UPF1*, up-frameshift suppressor 1 homolog; n.s., not significant; PS, psoriasis scales; PN, normal cornified epidermal layer.](IJMM-45-04-1163-g03){#f4-ijmm-45-04-1163}

![*AREG* triggers the NMD pathway post-transcriptionally, depending on its 3′UTR. (A) 293T cells were treated with DRB, and *AREG* mRNA levels were evaluated by RT-qPCR at 0, 3, 5, 7 and 10 h. The t~1/2~ represents the half-life of *AREG* mRNA. The *AREG* mRNA was stabilized by *UPF1* depletion, as detected by RT-qPCR. (B) The structures represent the expression vector for *AREG* ORF and *AREG*-3′UTR based on pEGFP-N1. (C) 293T cells were transfected with sh*UPF1*, and AREG expression vectors were transfected 24 h later. *AREG* mRNA levels were quantified 48 h after transfection. The 3′UTR region was required for NMD triggering by *AREG*. (D) Schematic representation of the dual-luciferase reporter system pEZX-*AREG*-3′UTR. (E) 293T cells co-transfected with pEZX-*AREG*-3′UTR plasmid together with sh*UPF1* or *UPF1* WT vector. Cells were collected and the FLuc activity was measured 48 h after transfection. RLuc activity was used as a control. The 3′UTR region was sufficient to trigger the NMD pathway. Data are presented as the mean ± SD from three independent experiments. ^\*\*\*^P\<0.001. *AREG*, amphiregulin; NMD, nonsense-mediated RNA decay; DRB, 5,6-dichloro-1-β-D-ribofuranosylben zimidazole; *UPF1*, up-frameshift suppressor 1 homolog; firefly luciferase, FLuc; *Renilla* luciferase, RLuc; ns, not significant; NC, normal cells; RT-qPCR, reverse transcription-quantitative PCR.](IJMM-45-04-1163-g04){#f5-ijmm-45-04-1163}

###### 

*UPF1* depletion-induced *AREG* disturbs keratinocyte homeostasis. (A) Cell counting kit-8 assays were performed to measure cell viability 48 h after *UPF1* or *AREG* knockdown in HEKα and HaCaT cells. *UPF1* and *AREG* depletion both decreased cell viability of keratinocytes. (B) The expression of *Ki67* decreased in keratinocytes with *UPF1* or *AREG* knockdown, while the expression of apoptosis-related gene *BAD* increased in both groups. (C) mRNA expression level of *K5*,*FLG* and *K10* was qualified by reverse transcription-quantitative PCR in keratinocytes. The expression levels of these differentiation makers decreased with *UPF1* depletion and were rescued by supplementary *AREG* depletion. (D) Representative human keratinocyte scratch wounds with cells treated with the sh*UPF1* construct, or sh*UPF1* combined with si*AREG*. The wound images at 0 and 24 h are presented, and the epidermal sheet edge indicated by the yellow irregular curve was identified by ImageJ software automatically. *UPF1* depletion induced the migration of keratinocytes by stabilization of *AREG*. (E) Quantitative analysis of the measured wound coverage at 0, 6, 12, 24 and 48 h. ^\*\*\*^P\<0.001 vs. NC group. (F) The motility markers *SNAI1*,*COX-2* and *MMP1* and two chemokines associated with nuclear factor κB activation, *CCL20* and *CXCL1*, were identified at the mRNA level in keratinocyte cells. Expression levels of the migration makers and chemokines increased with *UPF1* depletion and were rescued by supplementary *AREG* depletion. The results are presented as the mean ± SD from three independent experiments. ^\*\*\*^P\<0.001. *UPF1*, up-frameshift suppressor 1 homolog; *AREG*, amphiregulin;*BAD*, BCL2 associated agonist of cell death; *K5*, keratin-5; *FLG*, filaggrin; *K10*, keratin-10; *COX-2*, cyclooxygenase-2; *MMP1*, matrix metalloproteinase 1; *CCL20*, chemokine (C-C motif) ligand 20; *CXCL1*, human recombinant GRO-alpha; NC, normal cells; *Ki67*, proliferation marker protein Ki67; n.s., not significant.
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